Who Owns Sarepta Therapeutics Company?

Sarepta Therapeutics Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns Sarepta Therapeutics?

Recent events at Sarepta Therapeutics, including patient deaths linked to its gene therapy Elevidys and subsequent stock price drops, highlight the importance of understanding a company's ownership. This knowledge is crucial for grasping how ownership influences strategic decisions and accountability, especially during critical times.

Sarepta Therapeutics, founded in 1980 as Antivirals Inc. and later renamed, is a biopharmaceutical firm focused on genetic medicines for rare diseases like Duchenne muscular dystrophy. Its journey from its Oregon origins to its current base in Cambridge, Massachusetts, reflects a strategic evolution in the biopharmaceutical landscape.

Understanding who owns Sarepta Therapeutics is key to analyzing its strategic direction and response to challenges, especially following events impacting its gene therapy, Elevidys. This ownership structure, from founders to public shareholders, shapes the company's governance and decision-making processes.

As of December 2023, Sarepta employed 1,314 individuals. For 2024, the company reported preliminary total net product revenue of $1.79 billion, surpassing its guidance. By August 2025, its market capitalization was approximately A$2.73 billion (around $2.01 billion USD). The company's focus on developing precision genetic medicines for rare diseases, including advancements in treatments like those discussed in Sarepta Therapeutics PESTEL Analysis, positions it within a critical sector of healthcare innovation.

Sarepta Therapeutics, originally established as Antivirals Inc. on January 1, 1980, in Corvallis, Oregon, was founded by Dwight Weller and Milton Zuker. Initial funding for the company came from venture capital investments. Marwan Fawaz is also identified as a founder. The company's early focus was on antiviral therapies before expanding into broader biopharmaceutical development and rebranding as AVI BioPharma, Inc. in 1992.

Early Venture Capital Funding

The company's inception was supported by venture capital, indicating a structured approach to initial ownership designed to foster the development of new therapies.

Technological Evolution

A significant technological pivot occurred around the year 2000 when the company began to investigate NeuGene antisense technology.

Public Offering

The company completed its initial public offering (IPO) on June 4, 1997, under its original name, AntiVirals Inc.

Name Change

Following its IPO, the company officially changed its name to AVI BioPharma, Inc. in the same year, 1997.

Founders' Equity Details

Specific details regarding initial equity splits or early agreements, such as vesting schedules or buy-sell clauses, are not readily available in public records.

Strategic Shift

The company's strategic direction evolved from antiviral treatments to broader biopharmaceutical development, reflecting its adaptation to market opportunities.

The early ownership structure of Sarepta Therapeutics, then known as Antivirals Inc., was shaped by its founding in 1980 and its subsequent transition to a publicly traded entity. While specific details on founder equity and early agreements are not publicly disclosed, the reliance on venture capital for initial funding suggests a framework designed to support the company's growth and therapeutic development. The company's journey included a significant name change to AVI BioPharma, Inc. in 1997, the same year it went public, and a technological exploration into NeuGene antisense technology around 2000, all of which would have influenced its ownership landscape over time. Understanding the Target Market of Sarepta Therapeutics provides context for these early strategic decisions.

Founding and Early Development

Sarepta Therapeutics began its journey as Antivirals Inc. in 1980, with founders Dwight Weller and Milton Zuker. The company's initial capital was secured through venture capital investments.

• Founded: January 1, 1980
• Initial Name: Antivirals Inc.
• Founders: Dwight Weller, Milton Zuker
• Early Funding Source: Venture Capital
• Key Early Focus: Antiviral therapies

Sarepta Therapeutics SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Sarepta Therapeutics, initially known as AntiVirals Inc., became a publicly traded entity on June 4, 1997. Its evolution into a publicly traded company on NASDAQ under the symbol SRPT has shaped its ownership landscape, making it a subject of interest for understanding who owns Sarepta Therapeutics.

The Sarepta Therapeutics ownership structure is predominantly characterized by a significant presence of institutional investors and hedge funds, which collectively held approximately 86.68% of the company's stock as of August 2025. This substantial institutional backing, with 876 institutional owners holding over 111 million shares by June 30, 2025, indicates a strong reliance on large financial entities for capital and strategic oversight. Key players among these include BlackRock, Inc., holding 12,115,222 shares, Vanguard Group Inc. with 9,160,179 shares, State Street Corp. managing 4,695,027 shares, and D. E. Shaw & Co., Inc. with 4,478,638 shares. While mutual funds represented a considerable portion of this institutional ownership at around 54.70% in July 2025, insiders held a smaller stake of approximately 6.31%, and retail investors accounted for about 25.07%. The influence of these major shareholders is evident; for instance, a significant reduction of 8,562,435 shares by Capital International Investors in the second quarter of 2025 highlights the potential for substantial shifts in holdings. Such movements can directly impact the company's stock performance and strategic direction, as seen in the company's strategic restructuring in July 2025 aimed at cost reduction and strategic realignment, demonstrating how ownership dynamics can drive significant operational changes to ensure financial viability. Understanding the Sarepta Therapeutics stock ownership is crucial for grasping its market dynamics and strategic trajectory, a topic also explored in the Growth Strategy of Sarepta Therapeutics.

Key Shareholders in Sarepta Therapeutics

Institutional investors are the dominant force in Sarepta Therapeutics' ownership. Their substantial holdings reflect confidence in the company's long-term prospects.

• BlackRock, Inc. is a major institutional shareholder.
• Vanguard Group Inc. also holds a significant number of shares.
• State Street Corp. is another prominent institutional owner.
• Black Bear Offshore Master Fund LP is the largest individual shareholder.

Sarepta Therapeutics PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The current Board of Directors for Sarepta Therapeutics is instrumental in guiding the company's strategic direction and governance. As of September 2024, the board comprises nine directors, with a significant majority of eight being independent members. M. Kathleen Behrens, PhD, leads the board as Chairwoman, supported by directors including Richard J. Barry, Kathryn Boor, PhD, Michael Chambers, Deirdre Connelly, Douglas S. Ingram (also the CEO), Stephen L. Mayo, PhD, Claude Nicaise, MD, and Hans Wigzell, MD, PhD. Deirdre Connelly's addition in September 2024 bolstered the board with her extensive biopharmaceutical expertise.

Sarepta Therapeutics operates under a standard voting structure where each share of common stock carries one vote on all matters presented to shareholders. Director elections are decided by a majority of the votes cast. The company does not appear to utilize dual-class share structures or other mechanisms that would concentrate voting power. However, certain provisions within the company's governing documents, such as a requirement for a two-thirds affirmative vote to amend specific clauses, could serve as anti-takeover measures. Recent events, including a class action lawsuit filed in August 2025 concerning the gene therapy Elevidys and reported patient deaths, have intensified scrutiny on the company's governance and decision-making, potentially impacting future board composition and accountability.

Understanding Sarepta Therapeutics Stock Ownership

Sarepta Therapeutics is a publicly traded company, meaning its stock is available for purchase by the general public. This structure allows for broad ownership across individual investors and institutional entities. Understanding who owns Sarepta Therapeutics involves looking at filings from regulatory bodies that track major shareholders.

• Sarepta Therapeutics is publicly traded.
• Ownership is distributed among individual and institutional investors.
• Key executives and the board of directors also hold stock.
• Major shareholders are identified through regulatory filings.
• Information on Sarepta Therapeutics ownership can be found via investor relations.

For a deeper dive into the company's history and evolution, you can refer to this Brief History of Sarepta Therapeutics.

Sarepta Therapeutics Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Sarepta Therapeutics has navigated a dynamic period of ownership shifts and strategic realignments between 2020 and 2025. These changes reflect both internal restructuring and external market pressures impacting the biotechnology sector.

Institutional investors continue to play a significant role in Sarepta Therapeutics' ownership landscape, with notable shifts observed in recent quarters. While firms like D. E. Shaw & Co., Inc. increased their holdings in Q2 2025, others such as Capital International Investors reduced their stakes, indicating a period of active portfolio re-evaluation among major shareholders. This dynamic institutional activity underscores the ongoing assessment of the company's strategic direction and its ability to meet future financial obligations, particularly in light of recent operational adjustments and market challenges.

Key Leadership Appointments

In July 2025, Sarepta Therapeutics announced significant leadership changes to support its strategic restructuring. These appointments are designed to bolster operational efficiency and R&D focus.

Financial Restructuring Impact

The company's July 2025 workforce reduction of approximately 500 employees is projected to yield annual expense savings of around $400 million starting in 2026. This move aims to enhance financial stability and prioritize key development programs.

Regulatory and Legal Scrutiny

Recent events, including patient deaths associated with its gene therapy Elevidys, have led to FDA investigation and a class action lawsuit. This has resulted in a voluntary pause on shipments for certain patient groups.

Institutional Investor Activity

Major institutional investors are actively adjusting their positions, with some increasing stakes and others reducing them in Q2 2025. This reflects a complex market assessment of Sarepta Therapeutics' future prospects and Competitors Landscape of Sarepta Therapeutics.

Sarepta Therapeutics Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔